BioSpace News Archive

Magellan Health, Inc. announced that it has entered into an agreement with Starboard Value LP, which owns approximately 9.8% of the Company’s outstanding common stock.

Announced distribution partner for Melphalan Hydrochloride for Injection (EVOMELA®) to support commercialization in China following NMPA approval in December of 2018

Realm Therapeutics plc announces the completion of its previously announced Assets Disposal representing certain assets, which comprise the Vashe® wound care royalty stream, an FDA 510-cleared anti-itch hydrogel, which was formerly marketed as Aurstat™, HOCI related equipment, intellectual property, program records, and certain assigned contracts and intellectual property licenses.

Data presented at ADPD show that tau-targeted ZFP-TFs delivered with AAVs in mice and nonhuman primates have significant activity

Nuvo to Host Conference Call/Audio Webcast March 29th at 8:00 a.m. ET

The program is featured in a new documentary “Child of the Earth”

Pharmascience Inc. is proud to launch Prpms-PROGESTERONE 200 mg, the only 200 mg progestin capsule available in Canada for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma.

Adds 10 new THC-dominant strains to previously approved group, including unique 1:1 ratio strain

New Marketing Campaign Features Winfrey Speaking with WW Members About Why “It Works”

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device.